Fisher-Wallace Laboratories Inc

Fisher-Wallace Laboratories manufactures wearable transcranial electrical stimulation (tES) devices for neuropsychiatric conditions. The company's flagship product is OAK, a patent-pending, low-dose electrical brain stimulation headset designed to treat mood, sleep, and cognitive disorders with a 20-minute daily protocol requiring no Bluetooth or smartphone connectivity. OAK is currently in FDA clearance pathway with anticipated approval for anxiety treatment in Summer 2026, followed by depression and insomnia indications in 2027. The device has been studied in over 1,500 clinical trial participants and demonstrates safety and efficacy for Major Depressive Disorder, chronic insomnia, PTSD, Bipolar Depression, Parkinson's Disease, and Substance Use Disorder. A legacy Version 1.0 device, distributed under an FDA pathway that closed in 2019, remains in use by approximately 60,000 patients for maintenance and cognitive support. Research devices are currently deployed at the U.S. Department of Veterans Affairs. The company was co-founded by Chip Fisher and the late Dr. Martin Wallace, with Kelly Roman joining as co-founder and CEO. The company is backed by equity crowdfunding ($11 million raised from customers beginning in 2019) and seeks institutional investors for scaling across government, telemedicine, employer, and medical center channels. Clinical advisors include faculty from Harvard Medical School and Massachusetts General Hospital.